|View printer-friendly version|
Portola Announces Pricing of Public Offering of Common Stock
A registration statement relating to these securities has been filed with the
This announcement contains forward-looking statements, including statements relating to Portola Pharmaceuticals’ expectations regarding the completion, timing and size of the proposed public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected.
Investor Contact: Ana Kapor Portola Pharmaceuticals firstname.lastname@example.org Media Contact: Julie Normart W2O Group email@example.com